Page 44 - Haematologica Vol. 110 - January 2025
P. 44
REVIEW ARTICLE - Molecular pathogenesis and novel treatments for CMML L. Marando et al.
based therapy in chronic phase and blast transformed chronic myelomonocytic leukemia. Am J Hematol. 2021;96(11):E433-E436.
124. Montalban-Bravo G, Hammond D, DiNardo CD, et al. Activity of venetoclax-based therapy in chronic myelomonocytic leukemia. Leukemia. 2021;35(5):1494-1499.
125. Tremblay D, Csizmar CM, DiNardo CD, et al. Venetoclax (VEN) improves response rates but not survival in patients with chronic myelomonocytic leukemia (CMML) treated with hypomethylating agents (HMA): a multicenter, propensity score analysis. Blood. 2023;142(Supplement 1):321.
Haematologica | 110 January 2025
36
